Supporting the overall safety profile of PEG IFNα-2b, long-term subcutaneous administration over 48 weeks in patients with chronic hepatitis B has been shown to be well-tolerated, with a low incidence of severe adverse events, such as hematological changes, which were manageable and reversible upon discontinuation (Wang et al., 2024). Here, IFNA2 is linked to chronic hepatitis B virus infection.